Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (204)	7/14/2001 1:29:21 PM
From: keokalani'nui	Respond to of 1022

>>Which way are you leaning?<< Valuable lesson or not, I have made mistakes in the past trying to pick the best of competing development compounds. A good recent example was my unnecessary flip-flopping ownership of the peg-ifn's. I hate it, but sometimes on the clinical side I just have to throw up my hands or sometimes just throw up. I'm a middle-of-the road guy who thinks all 3 will be approved. But if I can twist your question to r/r, and this is no suck-up, the better investment is undoubtedly x507 hands down. A cheaper and better administration of remicade would make it tough on everyone however. Of the contestants, I own some bgen leaps and thankyou some btrn, and I luckily avoided some recent pain by having misgivings of DNA's late stage pipe. On that subject, when the ac delays looking at bosentan I'm thinking it may be time for a little of that in the 30s. Wilder edit: just saw the cite to your egfr work. Bet you're in the citations of that recent paper (and others).